Oragenics (OGEN) Accounts Payables (2010 - 2026)
Oragenics' (OGEN) quarterly Accounts Payables came in at $1.3 million in Q1 2026, up 6.35% YoY from $1.2 million in Q1 2025, and down 21.77% on a QoQ basis from $1.6 million in Q4 2025.
Oragenics (OGEN) Accounts Payables (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Accounts Payables data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Accounts Payables rose 6.35% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 6.35% YoY) and the FY2025 annual result came in at $1.6 million, up 18.01% from the prior year.
- Accounts Payables fell to $1.3 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $2.5 million in Q3 2025 to a low of $246690.0 in Q4 2022.
- A 5-year average of $1.2 million and a median of $1.3 million in 2026 frame the typical range for Accounts Payables.
- The widest YoY moves for Accounts Payables: up 1275.08% in 2022, down 37.89% in 2022.
- Tracing OGEN's Accounts Payables over 5 years: stood at $246690.0 in 2022, then surged by 498.19% to $1.5 million in 2023, then slipped by 8.12% to $1.4 million in 2024, then advanced by 18.01% to $1.6 million in 2025, then fell by 21.77% to $1.3 million in 2026.
- The last three Accounts Payables figures came in at $1.3 million (Q1 2026), $1.6 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | 1.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.82 Mn |
| Mar 31, 2026 | 1.25 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 2.50 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.38 Mn |
| Mar 31, 2024 | 695,791.00 |
| Dec 31, 2023 | 1.48 Mn |
| Sep 30, 2023 | 884,350.00 |
| Jun 30, 2023 | 951,019.00 |
| Mar 31, 2023 | 939,013.00 |
| Dec 31, 2022 | 246,690.00 |
| Sep 30, 2022 | 946,084.00 |
| Jun 30, 2022 | 1.28 Mn |
| Mar 31, 2022 | 1.09 Mn |
| Dec 31, 2021 | 17,940.00 |
| Sep 30, 2021 | 1.52 Mn |